Join the Campaign

Startup could bring back Vioxx for hemophilia

Small startup Tremeau Pharmaceuticals is engineering a comeback of Vioxx, which at one time delivered pain relief to millions of people with arthritis or other chronic pain. The former Merck & Co.

Small startup Tremeau Pharmaceuticals is engineering a comeback of Vioxx, which at one time delivered pain relief to millions of people with arthritis or other chronic pain. The former Merck & Co. product was taken off the market in 2004 after it was found to significantly inflate the risk of heart attack or stroke, but Tremeau is angling to reintroduce it as a treatment for severe joint pain associated with hemophilia. Vioxx has already received an orphan drug classification from U.S. regulators and could be approved within a few years, after patient testing has been conducted.

Ad Position: 
Bottom Center Aligned
Article URL: 
https://www.usnews.com/news/business/articles/2017-11-21/the-latest-startup-could-bring-back-vioxx-for-hemophilia
  • Join the Campaign
  • Take Action ALT Text
  • Get the facts ALT text
LATEST NEWS
October 17, 2017
October 17, 2017
APhA Executive Vice President and CEO Thomas E. Menighan, BSPharm, MBA, ScD (Hon), FAPhA, testified in a hearing about drug prices held by the...
Gag clauses, lack of provider status hinder cost-effective care, importation is no solution, APhA CEO says
MORE
August 14, 2017
August 14, 2017
Tennessee saw major provider status legislation take effect on July 1. “Pharmacists as Providers” (HB 405/SB 461) gives Tennessee pharmacists formal...
‘Pharmacists as providers’ legislation went into effect July 1
MORE
July 13, 2017
July 13, 2017
The Massachusetts Senate and House of Representatives health care committee held a hearing on legislation that would expand the scope of practice...
Hearing held last month included testimony from pharmacists and physicians
MORE
Advertisement